Clinical trial
Study Of "Continuous Use" Of Celecoxib Vs. "Usual or Intermittent Use"
NCT00139776 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00139776 |
|---|---|
| Title | Study Of "Continuous Use" Of Celecoxib Vs. "Usual or Intermittent Use" |
| Official title | Double-Blind Parallel-Group Randomized Study Of Efficacy And Safety Of "Continuous Use" Of Celecoxib Vs. The "Usual Use" Of Celecoxib In The Treatment Of Subjects With Chronic Osteoarthritis Of The Hip Or Knee Who Require an Anti-inflammatory Medication for Control Of Their Pain |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Osteoarthritis, Knee, Hip |
| Intervention type | Drug |
| Interventions | Celecoxib |
| Enrollment | 875 |
| Start date | Jul 1, 2005 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Aug 31, 2005 |
| Last update posted | Mar 29, 2021 |
| Countries | Belgium, Brazil, Canada, Chile, Colombia, France, United Kingdom, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: